A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST)

被引：0
|
作者：
Moulder, S. [1 ]
Adrada, B. [1 ]
Lim, B. [1 ]
Ueno, N. [1 ]
Candelaria, R. [1 ]
Rauch, G. [1 ]
Litton, J. [1 ]
Thompson, A. [2 ]
Huo, L. [1 ]
Hess, K. [1 ]
机构：
[1] Univ TX MD Anderson Canc Ctr, Houston, TX USA
[2] Baylor Coll Med, Houston, TX 77030 USA
来源：
BREAST | 2019年 / 44卷
关键词：
D O I：
10.1016/S0960-9776(19)30349-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P248
引用
收藏
页码：S101 / S102
页数：2
相关论文
共 50 条
  • [31] Artificial intelligence to accurately identify and select breast cancer patients with a pathologic complete response for omission of surgery after neoadjuvant systemic therapy: an international multicenter analysis
    Pfob, A.
    Sidey-Gibbons, C.
    Tasoulis, M. K.
    Lee, H. B.
    Koelbel, V
    Kuerer, H. M.
    Heil, J.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E88 - E88
  • [32] Artificial intelligence to accurately identify breast cancer patients with a pathologic complete response for omission of surgery after neoadjuvant systemic therapy: An international multicenter analysis.
    Pfob, Andre
    Sidey-Gibbons, Chris
    Tasoulis, Marios Konstantinos
    Lee, Han-Byoel
    Koelbel, Vivian
    Kuerer, Henry Mark
    Heil, Joerg
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Complete response (CR) to anthracycline-based chemotherapy using magnetic resonance imaging (MRI) predicts high rates of pathologic complete response (pCR) for triple negative breast cancer (TNBC) patients treated preoperatively with anthracycline and taxane-based regimens
    Marin Alcala, M.
    Llort Pursals, G.
    Del Riego Ferrari, J. H.
    Giner, J.
    Andreu Navarro, F. X.
    Medina, S.
    Aparicio, O.
    Dalmau Portulas, E.
    Ribera Fernandez, P.
    Oliveres, H.
    Martinez Vila, C.
    Cabrera Romero, J. M.
    Segui Palmer, M. A.
    Fernandez Morales, L. A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).
    Yam, Clinton
    Mittendorf, Elizabeth A.
    Sun, Ryan
    Huo, Lei
    Damodaran, Senthil
    Rauch, Gaiane M.
    Candelaria, Rosalind P.
    Adrada, Beatriz E.
    Seth, Sahil
    Symmans, William Fraser
    Murthy, Rashmi Krishna
    White, Jason B.
    Ravenberg, Elizabeth
    Clayborn, Alyson
    Prabhakaran, Sabitha
    Valero, Vicente
    Thompson, Alastair Mark
    Tripathy, Debu
    Moulder, Stacy L.
    Litton, Jennifer Keating
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer
    Jimenez, Jorge E.
    Abdelhafez, Abeer
    Mittendorf, Elizabeth A.
    Elshafeey, Nabil
    Yung, Joshua P.
    Litton, Jennifer K.
    Adrada, Beatriz E.
    Candelaria, Rosalind P.
    White, Jason
    Thompson, Alastair M.
    Huo, Lei
    Wei, Peng
    Tripathy, Debu
    Valero, Vicente
    Yam, Clinton
    Hazle, John D.
    Moulder, Stacy L.
    Yang, Wei T.
    Rauch, Gaiane M.
    EUROPEAN JOURNAL OF RADIOLOGY, 2022, 149
  • [36] Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study*
    Gianni, L.
    Huang, C. S.
    Egle, D.
    Bermejo, B.
    Zamagni, C.
    Thill, M.
    Anton, A.
    Zambelli, S.
    Bianchini, G.
    Russo, S.
    Ciruelos, E. M.
    Greil, R.
    Semiglazov, V
    Colleoni, M.
    Kelly, C.
    Mariani, G.
    Del Mastro, L.
    Maffeis, I
    Valagussa, P.
    Viale, G.
    ANNALS OF ONCOLOGY, 2022, 33 (05) : 534 - 543
  • [37] A tiered algorithm using mid-therapy ultrasound (US) response assessment and a novel gene expression signature (GES) improves the prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC): Results from the ARTEMIS trial (NCT02276443)
    Seth, Sahil
    Rauch, Gaiane M.
    Adrada, Beatriz
    Piwnica-Worms, Helen
    Hou, Lei
    Thompson, Alastair M.
    Symmans, William F.
    Lim, Bora
    White, Jason
    Draetta, Giulio F.
    Futreal, Andrew
    Chang, Jeffrey
    Moulder, Stacy
    CANCER RESEARCH, 2021, 81 (04)
  • [38] High pathological grade might discourage early invasive breast cancer patients who have a pathologic complete response to neoadjuvant systemic therapy from eliminating breast surgery
    Li, Chaofan
    Wang, Yusheng
    Liu, Mengjie
    Qu, Jingkun
    Zhang, Shuqun
    INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (02) : 1268 - 1270
  • [39] 47% pathologic complete response rate to anthracyclines-based associated with high cyclophosphamide doses neoadjuvant chemotherapy in basal-like and triple negative breast cancer patients
    Le, Tourneau C.
    Dettwiler, S.
    Laurence, V
    Alran, S.
    Beuzeboc, P.
    Pierga, J. Y.
    Frenaux, P.
    Sigal-Zafrani, B.
    Dieras, V
    Vincent-Salomon, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S169 - S169
  • [40] Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians
    Gass, Paul
    Untch, Michael
    Mueller, Volkmar
    Moebus, Volker
    Thomssen, Christoph
    Haeberle, Lothar
    Erber, Ramona
    Hein, Alexander
    Jud, Sebastian Michael
    Lux, Michael P.
    Hack, Carolin C.
    Hartmann, Arndt
    Kolberg, Hans-Christian
    Ettl, Johannes
    Lueftner, Diana
    Jackisch, Christian
    Beckmann, Matthias W.
    Janni, Wolfgang
    Schneeweiss, Andreas
    Fasching, Peter A.
    Nabieva, Naiba
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2018, 78 (07) : 707 - 714
12345